INSIGHTS ON CELL & GENE OUTSOURCING ISSUES

• Eliminating Barriers To In Vivo And Ex Vivo CAR-T Delivery

  Learn how lentiviral vector processes evolve for in vivo and ex vivo CAR‑T—covering yield, purity, scalability, and shifting regulatory demands for safe, consistent systemic delivery.

• Building On Pittsburgh's Legacy To Industrialize Advanced Therapies

  Pittsburgh's industrial roots and growing biotech hub unite to scale advanced therapies through new purpose‑built biomanufacturing, automation, and workforce development.

• Why Manufacturing Drives FDA CRLs In Cell Therapy

  Manufacturing and quality gaps drive most FDA Complete Response Letters in cell therapy, often stemming from early‑stage decisions and unresolved CMC issues that become major late‑stage approval risks.

• 10 Questions To Ask When Choosing A Cell Therapy CDMO

  A strategic framework outlines ten critical questions to evaluate a manufacturing partner’s reliability, expertise, performance, and operational rigor to ensure successful, scalable cell‑therapy development.

• A Faster Path To Genomic Medicine Feasibility

  Life Edit accelerates genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress.

• High‑Throughput Automation For Consistent Expression

  A high‑throughput, automated RNA‑seq workflow maintains uniform gene‑expression profiles across wide RNA inputs, enabling consistent library quality and scalable genomics on standard liquid‑handling platforms.

• Advanced Characterization Of Engineered T Cells

  Single‑cell sequencing and flow cytometry jointly profile engineered T‑cell products, revealing composition, function, and safety attributes to guide therapy platform development and quality control.

• Automated At‑Line Analysis vs. Traditional Flow Cytometry In Cell Therapy

  Cartridge‑based automated flow cytometry delivers phenotyping quality comparable to conventional methods while sharply reducing turnaround time and complexity across cell‑therapy materials and samples.

• A Closed, Digital Platform Delivers Consistent, Sterile, Scalable T‑Cell Production

  Explore an automated, closed cell‑therapy manufacturing system that boosts consistency, scalability, and quality while addressing donor variability and optimizing key process and performance parameters.

• Faster, Cheaper Cell Therapy with At‑Line QC

  Automated at‑line immunophenotyping QC streamlines cell therapy manufacturing, cutting turnaround time and cost while aligning with conventional methods and enabling scalable, reliable workflows.